


1 **Figure S1**



3 **Figure S1. TCellSI and heatmaps of T cells derived from Healthy Control, MM and CIDP**

4 **patients.** TCellSI algorithm scores quantifying functional T cell states: Regulating, Helper, and
5 Progenitor exhaustion. Heatmaps depicting expression levels of signature genes for selected T cell
6 states: (A) Regulating, (B) Helper and (C) Progenitor exhaustion. Data are presented as mean \pm SD.
7 Statistical significance was set at $p < 0.05$.

8

9


10

11

12

13

14 **Figure S2**



15

16 **Figure S2. CIDP-CAR-T cells exhibit comparable cytotoxicity to MM-CAR-T cells upon**
 17 **antigen encounter.** MM-CAR-T (n = 5) and CIDP-CAR-T (n = 5) cells were co-cultured with target
 18 cells expressing BCMA (U266^{BCMA-Mut-OE}) or CD19 (NALM-6). Secreted (A) TNF- α and (B) IL-2
 19 levels in co-culture supernatants of U266^{BCMA-Mut-OE} and NALM-6. Serial rechallenge assays
 20 assessed sustained cytotoxic function of MM-CAR-T (n = 5) and CIDP-CAR-T (n = 5) cells. (C)
 21 Schematic of sequential co-culture assay with fresh target cells (U266^{BCMA-mut-OE} or NALM-6) added
 22 every 24 h for 3 rounds (R1-R3) at E : T ratios of 1:5 and 1:10. (D) Assessment of sustained

23 cytotoxicity in the third round. CAR-T cells were pre-challenged with unlabeled targets prior to the
24 addition of fluorescently labeled targets in R3 to quantify specific lysis. Degranulation and perforin
25 expression were measured after 4 h of co-culture. Representative flow plots and quantification of
26 (E-F) CD107a⁺ and (G-H) Perforin⁺ cells within CD8⁺ CAR⁺ T cells. Data are presented as mean ±
27 SD. Statistical significance was set at $p < 0.05$.

28

29

30

31

32

33

34

35

36

37

38

39

40


41


42

43

44

45 **Figure S3**



59 **Figure S4**

60 **Figure S4. Gating strategy for T cell phenotype analysis. (A)** Flow cytometry gating strategy for
 61 determining the proportions of CD3⁺, CD4⁺, and CD8⁺ T cells in PBMCs from different sources.
 62
 63 **(B)** Gating strategy for assessing memory phenotypes in T cells from different sources. **(C)** Gating
 64 strategy for evaluating exhaustion phenotypes in T cells from different sources.

65

66

67

68

69


70

71


72

73

74 **Figure S5**



76 **Figure S5. Gating strategy for T cell functional analysis. (A)** Flow cytometry gating strategy for
77 determining the proportions of Granzyme B⁺ and Perforin⁺ CD8⁺ T cells from different sources. **(B)**
78 Flow cytometry gating strategy for determining the proportions of IFN- γ ⁺ and TNF- α ⁺ CD8⁺ T cells
79 from different sources.

82 **Figure S6**

83

84 **Figure S6. Gating strategy for CAR-T cell phenotype analysis. (A)** Flow cytometry gating85 strategy for determining the proportions of CD4⁺ and CD8⁺ T cells in CAR-T from different sources.86 **(B)** Gating strategy for assessing memory phenotypes in CAR-T cells from different sources. **(C)**


87 Gating strategy for evaluating exhaustion phenotypes in CAR-T cells from different sources.

88

89

90

91

92 **Figure S7**

93

94 **Figure S7. Gating strategy for CAR-T cell activation and cytotoxic function. (A)** Flow
 95 cytometry gating strategy for assessing CAR-T cell activation following co-culture with antigen-
 96 positive tumor cells. **(B)** Flow cytometry gating strategy for evaluating CAR-T cell cytotoxicity
 97 against antigen-positive tumor cells following co-culture.

98


99

100

101

102

103 **Figure S8**



104

105 **Figure S8. Gating strategy for CAR-T cell cytotoxic function. (A)** Flow cytometry gating
 106 strategy for determining the proportions of CD107a⁺ and Perforin⁺ CD8⁺ CAR-T cells following co-
 107 culture with antigen-positive tumor cells. **(B)** Flow cytometry gating strategy for evaluating CAR-
 108 T cell cytotoxicity against target cells following multiple rounds of co-culture with antigen-positive
 109 tumor cells.